MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- AJANTA PHARMA
AJANTA PHARMA Share Price 
(AJPH)
Here is the latest stock price and chart of AJANTA PHARMA. For more details, see the AJANTA PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Mar 20, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)1,022.00 | Open (Rs) 1,033.00 | High (Rs) 1,041.50 | Low (Rs) 1,015.00 |
| % Change-1.00 | Volume 21,993 | Value (Rs) 22,633,838 | 52-Week H/L 1,459.70 / 897.60 |
| Live NSE Quotes | Mar 20, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)1,021.05 | Open (Rs) 1,031.00 | High (Rs) 1,042.00 | Low (Rs) 1,016.75 |
| % Change-0.95 | Volume 424,849 | Value (Rs) 437,549,554 | 52-Week H/L 1,457.75 / 895.85 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 44.64 | P/E Ratio (x) 22.90 | Market Cap (Rs m) 89,884.90 | P/BV (x) 4.40 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
AJANTA PHARMA Share Price Today:
AJANTA PHARMA last traded price was down 1.0% to Rs 1,022.0 on the BSE. On the NSE, AJANTA PHARMA last traded price was down 1.0% to Rs 1,021.1. The total volume of shares traded was 0.4 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.1%. And the benchmark S&P BSE SENSEX was at 38,386.8 (up 0.1%).
Over the last 30 days, the AJANTA PHARMA share price is up 5.3%. And over the last one year, AJANTA PHARMA share price is down 25.9%.
|
| |
Today's Market
Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)
Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.
Related Views On News
AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)
Feb 1, 2019 | Updated on Feb 1, 2019For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)
Mar 8, 2019History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?
5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)
Mar 15, 20195 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.
Elections Don't Matter!(The Honest Truth)
Mar 13, 2019Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.
Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)
Mar 13, 2019The elements that fueled profit growth for these two companies led to a surge in their stock prices.
This is Why You Need to Buy Small Cap Stocks Now(The 5 Minute Wrapup)
Mar 15, 2019Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...
MoreTRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA - SANOFI INDIA COMPARISON
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.